November 6, 2025Blog
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World
NEWTON, Mass., November 6, 2025 – 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predicting tumor response to therapy, today announced it has been awarded “Antibody Detection Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
4D Path’s QPOR™ platform is designed to directly measure and quantify cell cycle deregulations and tumor immune microenvironment dynamics to provide unprecedented clarity into the collective tumor state and predict a patient’s response to therapy. QPOR™’s insights may help clinicians and researchers understand which treatments most effectively impact the cell cycle deregulations found in a patient’s tumor and lead to the most effective responses to treatment. In addition, the platform provides explainable, H&E-derived biomarker overlays on whole-slide images (WSIs) that can help inform IHC-antibody calibration within clinical-grade workflows through side-by-side comparison.
The end-to-end, fully automated platform requires no blood draws, sequencing, extra tissue, or clinical factors. QPOR™’s core methods originate in statistical physics and information theory (e.g., entropy) and quantify cell cycle deregulation and tumor–immune microenvironment dynamics from whole-slide images. QPOR captures treatment-relevant biology from digital images of standard H&E biopsies designed to enable scalable, cost-efficient, accurate treatment prediction without adding procedural burden. The result is a physics-informed, biology-grounded digital biomarker engine that helps identify likely responders and non-responders across tumor types and therapy classes.
The QPOR™ platform has demonstrated highly accurate therapeutic response prediction in multiple tumor types, across different therapeutic classes. This includes multiple clinical studies with high predictive performance to neoadjuvant chemotherapy and immunotherapy response in triple negative breast cancer and ER+/HER2– breast cancer patients.
“One of the biggest unmet needs in cancer is effective treatment prediction to match the right therapies for each patient. At 4D Path, we have invented something fundamentally new: our platform presents a fresh, physics-informed perspective on tumor dynamics and treatment prediction which provides actionable insights for personalized treatment selection. The 4D Path QPOR™ platform is being investigated in multiple clinical trials across solid tumor types, and we believe it is positioned to become a cornerstone of next-generation oncology treatment prediction and personalized care,” said Jacopo Leonardi, CEO of 4D Path. “We’re grateful for this acknowledgment from BioTech Breakthrough. While most companies in this space are building infrastructure or offering AI assistance to pathologists, we are delivering technology that can directly measure and quantify cell cycle deregulations, for the purpose of matching the right therapies for each patient.”
4D Path is currently building a broad, multi-indication portfolio of treatment predictive digital biomarkers, de-risked through academic and industry-sponsored trials across breast, bladder, ovarian, lung, and colorectal cancer. Leaders from Dana-Farber Cancer Institute, Yale Cancer Center, and other institutions serve on 4D Path’s Scientific Advisory Board.
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 15 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
“4D Path is redefining what’s possible in precision oncology. Cancer is driven by complex interactions within biological systems. However, current diagnostic methods measure molecular drivers of disease as tumor markers to infer response to therapy as opposed to intra/inter tumor dynamics. This doesn’t take into account or quantify the impact of complex multi-system interplay that is fundamental to cancer biology,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “4D Path is creating a new category of digital treatment prediction biomarkers — with real-world utility across discovery, trials, and clinical care — to power truly personalized, real-time treatment decisions. Congratulations on winning ‘Antibody Detection Solution of the Year!”
View the full winners list here: 5th Annual BioTech Breakthrough Awards Program Honors
####
About 4D Path
4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient’s response to therapy. This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.
For additional information, please visit www.4dpath.com or follow 4D Path on LinkedIn.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
PR Contact
Jordan Bouclin / Jill Anderson
SVM PR & Marketing Communications
Jordan.bouclin@svmpr.com / Jill.anderson@svmpr.com
(401) 490-9700